$90.99
0[0.00%]
Last update: 4:20PM Get Real Time Here
Haemonetics
(NYSE:HAE)Haemonetics Stock (NYSE:HAE), Analyst Ratings, Price Targets, Predictions
Haemonetics Corp has a consensus price target of $76.82, established from looking at the 42 latest analyst ratings. The last 3 analyst ratings were released from Barrington Research, Barrington Research, and Barrington Research on April 12, 2024, February 13, 2024, and November 3, 2023. With an average price target of $105 between Barrington Research, Barrington Research, and Barrington Research, there's an implied 15.40% upside for Haemonetics Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Barrington Research
Citigroup
Morgan Stanley
JMP Securities
Mizuho
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Haemonetics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/12/2024 | HAE | Buy Now | Haemonetics | $90.99 | 15.4% | Barrington Research | Michael Petusky | $105 → $105 | Maintains | Outperform | Get Alert |
| 02/13/2024 | HAE | Buy Now | Haemonetics | $90.99 | 15.4% | Barrington Research | Michael Petusky | → $105 | Reiterates | Outperform → Outperform | Get Alert |
| 11/03/2023 | HAE | Buy Now | Haemonetics | $90.99 | 15.4% | Barrington Research | Michael Petusky | $114 → $105 | Maintains | Outperform | Get Alert |
| 10/02/2023 | HAE | Buy Now | Haemonetics | $90.99 | 3.31% | Citigroup | Joanne Wuensch | $90 → $94 | Maintains | Neutral | Get Alert |
| 08/09/2023 | HAE | Buy Now | Haemonetics | $90.99 | 25.29% | Barrington Research | Michael Petusky | $111 → $114 | Maintains | Outperform | Get Alert |
| 05/12/2023 | HAE | Buy Now | Haemonetics | $90.99 | 21.99% | Barrington Research | Michael Petusky | $103 → $111 | Maintains | Outperform | Get Alert |
| 05/12/2023 | HAE | Buy Now | Haemonetics | $90.99 | 5.51% | Morgan Stanley | Drew Ranieri | $88 → $96 | Maintains | Equal-Weight | Get Alert |
| 05/12/2023 | HAE | Buy Now | Haemonetics | $90.99 | 26.39% | JMP Securities | David Turkaly | $105 → $115 | Maintains | Market Outperform | Get Alert |
| 02/08/2023 | HAE | Buy Now | Haemonetics | $90.99 | -3.29% | Morgan Stanley | Drew Ranieri | $84 → $88 | Maintains | Equal-Weight | Get Alert |
| 02/08/2023 | HAE | Buy Now | Haemonetics | $90.99 | 4.41% | Citigroup | Joanne Wuensch | $92 → $95 | Maintains | Neutral | Get Alert |
| 02/08/2023 | HAE | Buy Now | Haemonetics | $90.99 | 13.2% | Barrington Research | Michael Petusky | $94 → $103 | Maintains | Outperform | Get Alert |
| 02/08/2023 | HAE | Buy Now | Haemonetics | $90.99 | 26.39% | Mizuho | Anthony Petrone | $110 → $115 | Maintains | Buy | Get Alert |
| 01/24/2023 | HAE | Buy Now | Haemonetics | $90.99 | 20.89% | Mizuho | Anthony Petrone | $100 → $110 | Maintains | Buy | Get Alert |
| 01/06/2023 | HAE | Buy Now | Haemonetics | $90.99 | -7.68% | Morgan Stanley | Drew Ranieri | $90 → $84 | Maintains | Equal-Weight | Get Alert |
| 12/12/2022 | HAE | Buy Now | Haemonetics | $90.99 | 1.11% | Citigroup | Joanne Wuensch | $88 → $92 | Maintains | Neutral | Get Alert |
| 11/08/2022 | HAE | Buy Now | Haemonetics | $90.99 | 3.31% | Barrington Research | Michael Petusky | $88 → $94 | Maintains | Outperform | Get Alert |
| 11/08/2022 | HAE | Buy Now | Haemonetics | $90.99 | -1.09% | Morgan Stanley | Drew Ranieri | $85 → $90 | Maintains | Equal-Weight | Get Alert |
| 11/08/2022 | HAE | Buy Now | Haemonetics | $90.99 | 9.9% | Mizuho | Anthony Petrone | $90 → $100 | Maintains | Buy | Get Alert |
| 11/08/2022 | HAE | Buy Now | Haemonetics | $90.99 | 15.4% | JMP Securities | David Turkaly | $90 → $105 | Maintains | Market Outperform | Get Alert |
FAQ
What is the target price for Haemonetics (HAE)?
The latest price target for Haemonetics (NYSE: HAE) was reported by Barrington Research on April 12, 2024. The analyst firm set a price target for $105.00 expecting HAE to rise to within 12 months (a possible 15.40% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Haemonetics (HAE)?
The latest analyst rating for Haemonetics (NYSE: HAE) was provided by Barrington Research, and Haemonetics maintained their outperform rating.
When was the last upgrade for Haemonetics (HAE)?
The last upgrade for Haemonetics Corp happened on May 14, 2021 when CJS Securities raised their price target to N/A. CJS Securities previously had a market perform for Haemonetics Corp.
When was the last downgrade for Haemonetics (HAE)?
The last downgrade for Haemonetics Corp happened on January 27, 2022 when Needham changed their price target from N/A to N/A for Haemonetics Corp.
When is the next analyst rating going to be posted or updated for Haemonetics (HAE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Haemonetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Haemonetics was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
Is the Analyst Rating Haemonetics (HAE) correct?
While ratings are subjective and will change, the latest Haemonetics (HAE) rating was a maintained with a price target of $105.00 to $105.00. The current price Haemonetics (HAE) is trading at is $90.99, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.